{"title":"Cardiovascular aspects in the diagnosis and management of Turner’s syndrome","authors":"A. Borg, E. Brabant, M. Schmitt","doi":"10.1097/XCE.0000000000000020","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000020","url":null,"abstract":"Turner’s syndrome (TS) is a relatively common chromosomal abnormality frequently associated with cardiovascular abnormalities, such as a bicuspid aortic valve and coarctation of the aorta, as well as cardiovascular risk factors such as hypertension, hypothyroidism, and diabetes mellitus. Epidemiological studies have shown that these patients have increased cardiovascular morbidity and mortality. In addition, there is at least the theoretical potential that well-established treatments that are intended to address the short stature and hormonal deficiencies in these patients may negatively influence their cardiovascular risk profile. Further, the congenital structural abnormalities commonly found in TS, and long-term complications associated with them, warrant regular monitoring utilizing various cardiovascular imaging modalities to determine the need for timely surgical intervention. In this review, we summarize the main features of this syndrome, with emphasis on issues that impact the management, diagnostic work up, and monitoring of cardiovascular problems in adult patients with TS.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"60 1","pages":"45–58"},"PeriodicalIF":0.0,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86900708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"QTc prolongation and ventricular premature complexes secondary to insulin-induced hypoglycemia in a diabetic patient","authors":"Innocent Monya-Tambi, R. Castillo, Asma Syed","doi":"10.1097/XCE.0000000000000015","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000015","url":null,"abstract":"Cardiac arrhythmias may be caused by hypoglycemia in diabetic patients, with or without underlying cardiovascular disease. It may be difficult to establish a relationship between hypoglycemia alone and cardiac arrhythmia, especially in elderly diabetic patients, because of the presence of multiple comorbidities. We report a case of an elderly patient with diabetes and established cardiovascular disease, who presented with delirium secondary to severe hypoglycemia along with prolonged QTc interval and ventricular premature beats, which resolved after correction of hypoglycemia.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"10 1","pages":"79–81"},"PeriodicalIF":0.0,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75354739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sheep for the study of the urocortins and other hormones","authors":"M. Rademaker, C. Charles, M. Richards","doi":"10.1097/XCE.0000000000000024","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000024","url":null,"abstract":"The use of animal models has been crucial to our understanding of the causation, progression and therapeutic management of disease. The rapid ventricular pacing model of heart failure (HF) in sheep closely replicates the haemodynamic, endocrine and metabolic characteristics of severe human HF, and has been utilized extensively in the study of key and newly discovered hormones implicated in the pathophysiology of the syndrome. The large body size and blood volume of the sheep enable comprehensive instrumentation to provide diverse and multiple haemodynamic measurements and allow repeated blood and urine sampling – all of which are vital in capturing an integrated picture of the biological effects of HF and determining intersystem inter-relationships. This review focuses on the urocortin peptides as an example showing the range of studies carried out in this ovine model to help elucidate the pathophysiological role and therapeutic potential of a hormone in HF.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"89 1","pages":"39–43"},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73179012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New cardiovascular biomarkers in animal models: what can be expected in the coming years?","authors":"M. Oyama","doi":"10.1097/XCE.0000000000000026","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000026","url":null,"abstract":"Animal models of disease provide the basis for important scientific inquiry of proof of concept, drug safety and efficacy, and exploration of the mechanistic and pathophysiological aspects of disease. Animals with either induced cardiac disease or spontaneously occurring cardiac disease are test beds for new cardiovascular therapies or interventions. Biomarkers in animal models can help characterize disease, stratify risk of morbidity and mortality, and serve as surrogate endpoints. Biomarkers identify important similarities and differences between the animal model and the human condition. The future of biomarkers and animal models includes cross-organ investigation using multiorgan multimarker panels. Industry will use animal models and biomarkers to help shorten the time from drug discovery to market. Biomarker development has outpaced their acceptance in clinical use and carefully designed clinical studies are needed to achieve their maximum potential. Cardiovasc Endocrinol 3:27–31 c 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"44 1","pages":"27-31"},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84783438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Hunter, D. Terzic, N. E. Zois, L. Olsen, J. Goetze
{"title":"Pig models for the human heart failure syndrome","authors":"I. Hunter, D. Terzic, N. E. Zois, L. Olsen, J. Goetze","doi":"10.1097/XCE.0000000000000022","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000022","url":null,"abstract":"Human heart failure remains a challenging illness despite advances in the diagnosis and treatment of heart failure patients. There is a need for further improvement of our understanding of the failing myocardium and its molecular deterioration. Porcine models provide an important research tool in this respect as molecular changes can be examined in detail, which is simply not feasible in human patients. However, the human heart failure syndrome is based on symptoms and signs, where pig models mostly mimic the myocardial damage, but without decisive data on clinical presentation and, therefore, a heart failure diagnosis. In perspective, pig models are in need of some verification in terms of the clinical definition of the experimental condition. After all, humans are not pigs, pigs are not humans, and the difference between the species needs to be better understood before pig models can fully be used to elucidate the human heart failure syndrome. Cardiovasc Endocrinol 3:15–18 c 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"22 1","pages":"15-18"},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85179182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cardiovascular endocrinology in naturally occurring canine and feline models","authors":"J. Häggström, I. Ljungvall, K. Höglund","doi":"10.1097/XCE.0000000000000027","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000027","url":null,"abstract":"Rodents are frequently used to study aspects of cardiovascular endocrinology. The present review focuses on opportunities offered by naturally occurring heart disease in dogs and cats, that is larger animal models. In particular, the benefits of using these species include the possibility of studying the same types of naturally occurring diseases as those occurring in humans, and carrying out studies in genetically similar individuals (i.e. breeds) sharing the same environment as humans. Recent findings in neuroendocrine hormones, that is natriuretic peptides, components of the renin–angiotensin–aldosterone system, and endothelin-1, in dogs and cats are reviewed in this article. As in humans, all these hormones have been evaluated as cardiovascular biomarkers in dogs and cats, and natriuretic peptides have shown promise in the diagnosis, staging and prognostication of heart disease. However, components of the renin–angiotensin–aldosterone system and endothelin-1 appear to be more useful as functional biomarkers for monitoring compensatory responses to naturally occurring heart diseases and their treatments.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"77 1 1","pages":"32–38"},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83433454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Natriuretic peptides in animal models of cardiovascular disease","authors":"D. Burley, Justin S. Bice, G. Baxter","doi":"10.1097/XCE.0000000000000025","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000025","url":null,"abstract":"Natriuretic peptides play a major role in cardiovascular homeostasis, and much of our knowledge on this stems from animal studies looking into the genetic knockout or overexpression of natriuretic peptides or their biological target, the natriuretic peptide receptor. Genetic perturbation of the natriuretic peptide system in rodents causes systemic hypertension, cardiac fibrosis, left ventricular hypertrophy, and heart failure. Moreover, animal models of acute myocardial infarction and heart failure have demonstrated the therapeutic potential of exogenously administered natriuretic peptides in treating human acute coronary syndromes and heart failure. In this review, we hope to highlight the importance of animal models in helping us understand the biological function and consequence of the natriuretic peptide system in cardiovascular disease.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"36 1","pages":"19–26"},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81055582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ernest Henry Starling: the history of cardiovascular endocrinology and the continuous need for developing animal models","authors":"J. Henriksen","doi":"10.1097/XCE.0000000000000021","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000021","url":null,"abstract":"Introduction The English physiologist, Ernest Henry Starling (1866–1927) (Fig. 1) in 1896, provided a quantitative explanation of the transcapillary transport of fluid. Six years later, he discovered the first hormone and introduced the concept of hormones in 1905, and at the time of the First World War, he formulated the fundamental law on the mechanical effect of the mammalian heart [1–3]. The transcapillary fluid transport, the hormone concept and the law of the heart all bear witness to a remarkable individual with an ability to interpret experimental data comprehensively and critically. All physicians today are trained in this fundamental physiological knowledge as a matter of course, but Starling’s numerous publications from 1890 to 1928 contributed considerably towards the transition of circulatory physiology from a qualitative discipline to a quantitative science. The present paper deals with Starling’s achievements in cardiovascular physiology and endocrinology.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"7 1","pages":"2-8"},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84956548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nora E. Zoisa, Henrik D. Pedersenc, Jens Häggströmd, Lisbeth H. Olsenb
{"title":"Echocardiographic assessment of left ventricular function in mitral regurgitation: is the dog a useful model of man?","authors":"Nora E. Zoisa, Henrik D. Pedersenc, Jens Häggströmd, Lisbeth H. Olsenb","doi":"10.1097/XCE.0000000000000028","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000028","url":null,"abstract":"Myxomatous mitral valve disease (MMVD) is the most common cause of primary mitral regurgitation in humans and the most common cardiac disease in dogs. Many similarities have been described and, therefore, the dog is considered to be a suitable natural model for MMVD in humans. Accurate identification of incipient myocardial deterioration is crucial to optimally time interventional surgery. Nonetheless, this issue is still an object of controversy. In this respect, studies of left ventricular (LV) function in dogs with MMVD could potentially be useful. The present review compares the results obtained in echocardiographic studies of LV function in humans and dogs with MMVD. Although different study designs pose a limitation and results within the two species are not entirely concordant, it appears that LV function is better preserved in small-sized and medium-sized dogs than in humans. This may limit the usefulness of dogs as a model for LV function in MMVD. Cardiovasc Endocrinol 3:9–14 c 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"115 1","pages":"9-14"},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83773537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Conference report: World Congress on insulin resistance, diabetes and cardiovascular disease, Los Angeles, 7–9 November 2013","authors":"A. Krentz","doi":"10.1097/XCE.0000000000000030","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000030","url":null,"abstract":"Here I offer a few brief highlights from what was one of the most stimulating metabolism conferences I have attended in some time. Such was the range of topics, which testifies to the position insulin resistance has assumed in the pathogenesis of so many human diseases, that this report must be selective. The clinical disorders of greatest relevance from a public health perspective – that is, diabetes and cardiovascular disease – are now incorporated into the title of the conference. Other topics, such as the role of insulin resistance in cancer, lipid metabolism obesity and fatty liver disease, were also well represented over the course of the 3 days. Although some reminders of lessons from the past were included, the conference was perhaps notable above all for the plethora of new data on areas that connected molecular biology to clinical syndromes and to proven and novel therapeutic options. Discussion of the topics presented was both lively and of the highest scientific standard. As expected, more questions remain than were unequivocally answered in what was a state-of-the-art summary of this diverse and fascinating, and still largely enigmatic, topic.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79237724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}